AUPH Share Price Performance
US$14.99
7.44 (98.54%)
10.1% undervalued intrinsic discount
US$16.67
Fair Value
Price US$14.99
AnalystConsensusTarget US$16.67
AnalystHighTarget US$21.00
AnalystLowTarget US$9.00
Fair ValueUS$16.67
Share Pricen/a
Aurinia Pharmaceuticals Inc. Stock Price
- 3 Narratives written by author
- 1 Comments on narratives written by author
- 29 Fair Values set on narratives written by author
AUPH Community Narratives
AN
Fair Value US$16.67 10.1% undervalued intrinsic discount
AUPH: Future Opportunities Will Depend On Pipeline Clarity And Risk Developments
0users have liked this narrative
1users have commented on this narrative
12users have followed this narrative
AN
Fair Value US$21 28.6% undervalued intrinsic discount
Aging Demographics And LUPKYNIS Uptake Will Expand Markets
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$9 66.6% overvalued intrinsic discount
Increasing Pricing Pressures And Limited Pipeline Will Weaken Outlook
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Aging Demographics And LUPKYNIS Uptake Will Expand Markets
Key Takeaways Rapidly growing adoption of LUPKYNIS and expanded treatment guidelines are strengthening revenue growth and improving profitability through longer patient use and greater prescriber confidence. Diversified autoimmune pipeline, operational efficiency, and shareholder-friendly capital allocation are positioning Aurinia for superior long-term growth, margin improvement, and increased earnings per share.Read more
13
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$21
28.6% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
27.29% p.a.
Profit Margin
50.63%
Future PE
10.68x
Price in 2029
US$25.4
AUPH: Future Opportunities Will Depend On Pipeline Clarity And Risk Developments
Key Takeaways Accelerated LUPKYNIS adoption and a promising pipeline support long-term growth amid rising autoimmune disease prevalence and favorable regulatory trends. Enhanced operational efficiency and robust IP strategy boost margins and shield against competition, while share buybacks underscore confidence in sustained profitability.Read more
141
users have viewed this narrative0users have liked this narrative
1users have commented on this narrative
12users have followed this narrative
AN
US$16.67
10.1% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
17.73% p.a.
Profit Margin
37.5%
Future PE
14.46x
Price in 2028
US$20.17
Increasing Pricing Pressures And Limited Pipeline Will Weaken Outlook
Key Takeaways Reliance on a single marketed drug amid intensifying competition and pricing pressures threatens revenue stability and long-term profitability. Limited pipeline progress and stricter regulatory hurdles raise concerns about sustained growth and valuation resilience.Read more
2
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$9
66.6% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
9.77% p.a.
Profit Margin
25.04%
Future PE
13.23x
Price in 2028
US$10.77
Trending Discussion
Recently Updated Narratives
AN
AUPH: Higher Fair Value View Will Hinge On Lupus Nephritis Franchise
Fair Value: US$21 28.6% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AUPH: Legal Overhang And Pipeline Clarity Will Shape Balanced Near-Term Outlook
Fair Value: US$16.67 10.1% undervalued intrinsic discount
12 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
Increasing Pricing Pressures And Limited Pipeline Will Weaken Outlook
Fair Value: US$9 66.6% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Aurinia Pharmaceuticals Inc. Key Details
About AUPH
- Founded
- 1993
- Employees
- 130
- CEO
- WebsiteView website
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
